Clinical trials: Aggressive B-Cell Non-Hodgkin Lymphoma
Lymphoma
Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma
Phase II Study of Avastin Plus Rituximab for Patients with Relapsed and Chemotherapy - or Rituxan Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma.
- Trial name
- NCT00081861
- Testing
- Avastin, Rituximab
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
This phase II trial is studying how well PXD101 works in treating patients with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.
- Trial name
- NCT00303953
- Testing
- belinostat
- Where
- 123 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL)
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
This study will identify the highest dose, and assess the safety, of cerdulatinib (PRT062070) that may be given in participants with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or non-hodgkin…
- Conditions
- Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), T-cell Lymphoma (PTCL and CTCL)
- Trial name
- NCT01994382
- Testing
- Cerdulatinib, Rituximab
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma.
- Conditions
- Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL)
- Trial name
- NCT05583149
- Testing
- ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Patrick C. Johnson, MD
Lymphoma
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00278408
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- 152 sites in Denmark, Germany and 2 more
- Volunteers
- 700 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
Lymphoma
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00290706
- Testing
- bortezomib, gemcitabine hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Northwestern University
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
This clinical trial studies the side effects and best dose of giving fludarabine and total-body irradiation (TBI) together followed by a donor stem cell transplant and cyclosporine and mycophenolate mofetil in treating human…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00112593
- Testing
- fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
This phase I/II trial studies the side effects and best dose of donor natural killer (NK) cell therapy and to see how well it works when given together with fludarabine phosphate, cyclophosphamide, total-body irradiation, donor…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT00789776
- Testing
- Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Fred Hutchinson Cancer Center
Relapsed/Refractory Aggressive B-Cell Malignancies
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
This is a Phase 1/2 study to investigate the safety and efficacy of the CAR-T therapy, ONCT-808, in patients with relapsed/refractory (R/R) aggressive B cell malignancies.
- Trial name
- NCT05588440
- Testing
- ONCT-808, Bridging Therapy
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Oncternal Therapeutics, Inc
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
This randomized phase III trial studies how well graft-vs-host disease (GVHD) prophylaxis works in treating patients with hematologic malignancies undergoing unrelated donor peripheral blood stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT01231412
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate
- Where
- 11 sites in United States, Denmark and 1 more
- Volunteers
- 174 people
- Sponsor
- Fred Hutchinson Cancer Center
Relapsed/Refractory Aggressive B-cell Lymphomas
Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas
This is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + MEDI0680 in participants with relapsed or refractory aggressive B-cell lymphomas who have failed 1-2 prior lines of therapy.
- Trial name
- NCT02271945
- Testing
- MEDI-551 12 mg/kg, MEDI0680 2.5 mg/kg, MEDI0680 10 mg/kg
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- MedImmune LLC
Lymphoma, Non-Hodgkin
A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas
The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory…
- Trial name
- TRANSFORM (NCT03575351)
- Testing
- Standard of Care, JCAR017
- Where
- 54 sites in United States, Belgium and 10 more
- Volunteers
- 184 people
- Sponsor
- Celgene
AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
This partially randomized phase I/II trial studies the side effects and the best dose of vorinostat when given together with combination chemotherapy and rituximab to see how well it works compared to combination chemotherapy…
- Conditions
- AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage I Grade 3 Follicular Lymphoma
- Trial name
- NCT01193842
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
- Where
- 35 sites in United States
- Volunteers
- 107 people
- Sponsor
- National Cancer Institute (NCI)
Hematologic Malignancies, Solid Tumor
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
- Trial name
- NCT02663518
- Testing
- PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
- Where
- 51 sites in United States, Canada
- Volunteers
- 249 people
- Sponsor
- Pfizer
Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
This phase II trial studies how well sirolimus, cyclosporine and mycophenolate mofetil works in preventing graft-vs-host disease (GVHD) in patients with blood cancer undergoing donor peripheral blood stem cell (PBSC) transplant.
- Conditions
- Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, Adult Diffuse Large B-Cell Lymphoma, Adult Myelodysplastic Syndrome
- Trial name
- NCT01251575
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate
- Where
- 5 sites in United States, Denmark
- Volunteers
- 77 people
- Sponsor
- Fred Hutchinson Cancer Center
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL
This randomized phase III trial studies 90-yttrium ibritumomab tiuxetan and combination chemotherapy compared with combination chemotherapy alone before stem cell transplant in treating patients with diffuse large b-cell…
- Trial name
- SPINOZA (NCT02366663)
- Testing
- 90-Yttrium Ibritumomab tiuxetan, Carmustine, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- City of Hope Medical Center
Non-Hodgkin Lymphoma
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma…
- Trial name
- SUNMO (NCT05171647)
- Testing
- Mosunetuzumab, Polatuzumab vedotin, Tocilizumab
- Where
- 50 sites in United States, Argentina and 11 more
- Volunteers
- 208 people
- Sponsor
- Hoffmann-La Roche
Lymphoma
Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as dexamethasone, cisplatin, gemcitabine, and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00078949
- Testing
- rituximab, cisplatin, cytarabine
- Where
- 27 sites in United States, Australia and 1 more
- Volunteers
- 849 people
- Sponsor
- NCIC Clinical Trials Group
Lymphoma
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00004031
- Testing
- rituximab, CHOP regimen, carmustine
- Where
- 15 sites in United States, Canada
- Volunteers
- 397 people
- Sponsor
- SWOG Cancer Research Network
Lymphoma, B-cell Non-Hodgkin's Lymphoma
Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL
The purpose of this research is to study a treatment program for patients with aggressive lymphoma that has come back after initial or first therapy (called relapsed) or that has not responded to first therapy (called…
- Trial name
- NCT00588094
- Testing
- Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center